The Future of Pharma: How to succeed with artificial intelligence
The use of Artificial Intelligence (AI) has had a tremendous impact on nearly every industry over the last several years. The promise AI holds for organizations to decrease the costs, while increasing the speed and accuracy associated with core and secondary activities has driven significant investments. Our panel of experts share how artificial intelligence is set to change the drug lifecycle, with a particular focus on the impact to business development and licensing and regulatory affairs.
Winning in global regulatory with AI: Advancing compliance, increasing approval rates and simplifying market expansion
Join us for the second session of our Future of Pharma digital event: Winning in global regulatory with AI: Advancing compliance, increasing approval rates and simplifying market expansion
In this session, we will explore how AI can help you and your organization:
• Understand key trends in the application of AI in the regulatory space from both a pharma and an agency/HTA point of view
• Inform regulatory strategy, affairs and operations of changing regulations to respond accordingly
• Identify and overcome potential obstacles and barriers to success while uncovering opportunities to improve performance
• Adopt greater collaboration and communication with business development and licensing colleagues and other areas of the business to increase drug and program success
Accurately and quickly derive the benefits of AI within your business while powering your regulatory strategy forward with strategic communication within the organization to increase success.
Using AI and Competitive Intelligence for portfolio prioritization and evaluating external assets
The use of Artificial Intelligence (AI) across the pharmaceutical value chain was once theory. But it is quickly becoming the new reality for the industry. Across the drug development process, AI is being used to uncover hidden insights, manage complex data, drive efficiencies and reduce growing costs. While we are hearing an increasing number of use cases across the R&D and clinical space, we’ve yet to hear comprehensive insight into how other core functions can benefit from this innovative technology.